Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $25.20

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.20.

ATXS has been the topic of a number of recent research reports. TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, Oppenheimer boosted their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th.

Astria Therapeutics Trading Up 0.8 %

NASDAQ:ATXS opened at $11.23 on Tuesday. The company has a market capitalization of $633.60 million, a P/E ratio of -4.84 and a beta of 0.71. Astria Therapeutics has a 12 month low of $4.26 and a 12 month high of $16.90. The firm has a fifty day simple moving average of $11.23 and a 200-day simple moving average of $10.98.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Equities analysts forecast that Astria Therapeutics will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in shares of Astria Therapeutics during the 1st quarter worth about $62,115,000. Perceptive Advisors LLC increased its position in shares of Astria Therapeutics by 82.9% in the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Astria Therapeutics during the 4th quarter worth approximately $12,119,000. Artal Group S.A. purchased a new position in shares of Astria Therapeutics during the 1st quarter valued at approximately $12,445,000. Finally, Nantahala Capital Management LLC acquired a new stake in Astria Therapeutics in the 2nd quarter valued at $6,142,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.